Morgan Stanley analyst Erin Wright has maintained their bullish stance on UNH stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Erin Wright has given his Buy rating due to a combination of factors that indicate a positive outlook for UnitedHealth. The company is actively addressing operational improvements at Optum Health, focusing on stabilizing its value-based care platform and optimizing care delivery businesses. These efforts are expected to enhance sustainability and improve long-term target margins.
Additionally, UnitedHealth’s management maintains a positive outlook on Medicare Advantage (MA) pre-tax margin progression, with expectations of reaching higher margins in the coming years. The company is also working on improving its MA membership in high-rated plans, which should bolster profit recovery. These strategic initiatives and the commitment to operational enhancements underpin Erin Wright’s confidence in UnitedHealth’s growth potential, leading to the Buy rating.
In another report released today, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $386.00 price target.
Based on the recent corporate insider activity of 138 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UNH in relation to earlier this year.